Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-label, Randomised Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment

NCT06651970 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06651970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06651970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-label, Randomised Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Recruiting
Start date
February 4, 2025
Completion date
September 30, 2032
Enrollment
60 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia, moderate to severe cardiac impairment